Core Viewpoint - Banco Macro's stock is currently in a bearish outlook following a breakdown of its Cakra structure, indicating systemic weakness in both its ADR and home-country listing [5][6]. Summary by Sections Adhishthana Cycle Overview - Banco Macro is in Phase 8 of its 18-phase Adhishthana cycle, with a transition from Phase 4 in September 2022 through Phase 6, before entering a problematic Phase 7 [1][2]. Phase 7 Dynamics - In Phase 7, Banco Macro experienced a significant decline, breaking below its Cakra and triggering the Move of Pralaya, which is characterized by strong selling pressure [3][4]. Stock Performance - The stock price of Banco Macro fell from approximately $80 to around $40, representing a decline of over 50% [4]. Investor Outlook - The breakdown of the Cakra suggests a bearish outlook for Banco Macro, with potential underperformance extending until 2029 due to the Guna Triads not beginning until then [5][6]. Market Sentiment - Despite buy ratings from institutions like HSBC, the stock is not considered a value play, and any short-term rallies are unlikely to be sustainable [6][7].

Core Insights - FIS is currently in Phase 15 of its 18-phase Adhishthana cycle, with a troubling outlook under the Adhishthana Principles [1] FIS Weekly Cycle So Far - FIS formed a Cakra structure between Phases 4-8 over approximately 1,200 days, which typically has bullish implications [2][4] - The stock broke out of the Cakra to the downside in Phase 9, leading to a significant decline known as the Move of Pralaya [4][5] Current Position of FIS - FIS is now in its Guna Triads, specifically Phases 14, 15, and 16, which are critical for achieving Nirvana in Phase 18 [6] - There are no signs of Satoguna in Phase 15, making a Nirvana move in Phase 18 unlikely [6] Investor Outlook - The stock has already experienced a Cakra breakdown and a Move of Pralaya, resulting in a decline of approximately 68%, from $150 to $45 [5][9] - Despite some analysts upgrading the stock, the overall picture under the Adhishthana Principles indicates continued risk [9] - If Phase 16 concludes without signs of strength, the stock's prospects remain bleak, suggesting that treating FIS as a value buy may be premature [10]

Core Insights - Amer Sports is currently in Phase 2 of its Adhishthana cycle, which consists of two parts: the Sankhya period and the Buddhi period [2][4] - The stock has experienced a significant rally from approximately $20 to $40 during the Sankhya period, which typically indicates weakness or consolidation [4] - A correction of about 20% occurred as the stock transitioned towards the Buddhi period, dropping from $42 to $32 [4] Market Sentiment - The current rally is viewed with skepticism as it is occurring in the wrong period of Phase 2, which may not be sustainable [6] - Despite some firms remaining bullish, caution is advised due to the misalignment with the Adhishthana Principles [6] - Heavy call writing in out-of-the-money strikes indicates market skepticism [6] Future Outlook - Phase 2 is expected to continue until May 2026, with a clearer setup anticipated only after the Yajña formation begins [6] - Patience is recommended as the best strategy for investors at this time [6]

Core Viewpoint - uniQure's stock experienced a significant surge of approximately 250% following positive results from its gene therapy for Huntington's disease, but the Adhishthana Principles suggest a more cautious outlook for investors [1][11]. Company Journey - uniQure has undergone an 18-phase Adhishthana cycle, currently in Phase 17, which is characterized by a historical pattern of forming a Cakra between Phases 4 and 8, typically indicating bullish trends [2]. - The stock initially formed its Cakra in Phase 4 but broke down during Phase 8, leading to a bearish signal known as the Move of Pralaya, resulting in a decline from $60 to $5 over more than 1,400 days [4][6]. Current Outlook - In Phase 17, the principles advise against new trades due to a weak Guna Triad and lack of a clear bullish setup, raising concerns about the sustainability of the recent price spike [9]. - The stock has already broken its Cakra, indicating potential fundamental issues, and has announced a $200 million underwritten public offering, further complicating the outlook [10]. Investor Outlook - While the medical data regarding Huntington's disease is promising, the Adhishthana cycle indicates that the recent rally may not be sustainable, suggesting that investors should wait for clearer signals before making new investments [11].

Core Insights - ICF International is currently experiencing a significant decline in stock price, dropping from approximately $180 to around $84 since November 2024, indicating a bearish outlook according to the Adhishthana Principles [1][5][7] - The stock has broken a critical Cakra formation, triggering a bearish signal known as the Move of Pralaya, which suggests deeper weakness ahead [1][3][5] Stock Performance - The stock's decline represents a drop of roughly 45% from its previous highs, with historical data indicating that this underperformance may continue until the Guna Triads begin in mid-2029 [5][7] - The Cakra formation typically indicates bullish implications; however, ICF International's failure to maintain this structure has led to a significant bearish trend [2][3] Structural and Fundamental Issues - A breakdown of the Cakra formation may signal potential underlying structural or fundamental issues within ICF International that are not yet apparent [6] - The current outlook for ICF International remains bearish, and investors considering a value buy are advised to delay their decisions due to the implications of the Move of Pralaya [7]

Bloom Energy BE has staged a powerful rally since July, climbing from $24 to nearly $85 in just a few months. When analyzed through the lens of the Adhishthana Principles, the move reveals a clear structural story on why the stock has been rallying and what may lie ahead. Bloom Energy & Its Cakra FormationUnder the Adhishthana Principles, stocks typically form a Cakra between Phases 4 and 8. This structure resembles a channel with an arc and usually carries bullish implications. A decisive breakout in Phase ...

Core Viewpoint - NeoGenomics (NEO) is currently in Phase 18 of its Adhishthana Cycle, indicating a prolonged period of consolidation with little sign of breakout until August 2026 [1][10]. Summary by Sections NEO's Cycle Overview - NEO has closely followed the Adhishthana Principles throughout its cycle, particularly between Phases 9 and 12, demonstrating a strong alignment with the model [2]. - Stocks in Phases 4 through 8 typically form a Cakra, which has bullish implications, leading to a breakout in Phase 9, marking the start of the Himalayan Formation [3]. Historical Performance - From May 2016 to September 2019, NEO traded within its Cakra, then broke out sharply in Phase 9, rising from $18 to $34 [5]. - The stock continued to rally in Phase 10, reaching a peak of $61, but subsequently began to decline, falling over 70% back to the breakout level near $18 [6]. Challenges Faced - The issues for NEO began upon entering the Guna Triads (Phases 14, 15, and 16), which are critical for determining the potential for achieving Nirvana in Phase 18 [7]. - For Nirvana to occur, the Guna Triads must exhibit Satoguna, indicating a sustainable bullish move, which NEO failed to demonstrate [8]. Current Status and Outlook - NEO remains in consolidation for over 850 days, with the current phase concluding in August 2026, suggesting continued stagnation [10]. - Investors are advised to be cautious, as the stock is unlikely to show significant movement in the near term, remaining "stuck in the Matrix" [11].

Core Viewpoint - Astera Labs has experienced a significant rally recently, but this movement raises concerns when analyzed through the Adhishthana Principles, particularly as it is currently in the first leg of Phase 2 of its 18-phase cycle, where such sharp moves often do not sustain [1][6]. Group 1: Phase Analysis - Phase 2 of the Adhishthana framework is divided into two periods: Sankhya and Buddhi [2]. - Astera Labs is currently in the Sankhya period, which is characterized by a lack of bullish strength and often leads to instability [4][9]. - Historical examples, such as e.l.f. Beauty, show that rallies during the Sankhya period can lead to sharp corrections once the Buddhi period begins [5]. Group 2: Investor Outlook - While short-term momentum for Astera Labs may continue, the cycle structure indicates potential turbulence ahead, particularly when the Buddhi period starts around October 2025 [6]. - Existing investors are advised to consider hedging strategies to manage downside risk, while new investors should be cautious about entering the market during this rally [7].

Core Viewpoint - Globant is currently experiencing a prolonged period of weakness in its stock performance, as indicated by its position in the Adhishthana cycle, particularly in Phase 16 of 18 phases [1][10]. Monthly Chart Analysis - On the monthly chart, Globant is in Phase 3, characterized by the Adhishthana Yajña formation, which has seen the stock decline approximately 72% from its peak of $238 to $66 [2]. - The decline can be traced back to Phase 2, which consists of two distinct parts, where the stock initially showed significant bullish sentiment, rising by 425% during the Sankhya period, only to be punished in the Buddhi period [5][3]. Weekly Chart Analysis - The weekly chart indicates that Globant is in Phase 16, progressing through the Guna Triads, which are critical for determining the potential for achieving Nirvana in Phase 18 [7][10]. - There has been no indication of bullish sentiment (Satoguna) in Phases 14, 15, or 16, suggesting a low likelihood of reaching Nirvana in Phase 18, which begins in June next year [10][11]. Investor Outlook - The stock is under pressure in both monthly and weekly cycles, with expectations of retesting the Phase 2 low near $46 before any potential rebound [11]. - The absence of Satoguna across the triads implies that any future movements are likely to be characterized by slump and consolidation rather than a sustained recovery [11].

Core Insights - CAVA Group's recent stock decline is attributed to misalignment in its current Phase 2 of the Adhishthana cycle, leading to prolonged volatility [1][6] - The stock's performance deviated from expected patterns, resulting in a full retracement of earlier gains [4][5] Phase Analysis - CAVA is currently in Phase 2, which consists of two distinct parts, but it did not follow the ideal structure, leading to an unsustainable rally [2][5] - The expected behavior during the Sankhya period is consolidation, but CAVA experienced an early rally instead, which has contributed to the current selloff [4][5] Investor Outlook - Given the misalignment in Phase 2, caution is advised for investors, as the stock is still in a no-action zone in Phase 1 [6][7] - Investors are recommended to avoid new positions until the stock structure realigns with the Adhishthana Principles [6][7]